Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma	pancreatic ductal adenocarcinoma	Active, not recruiting	Phase 1	2025-09-05		NCT05209074

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Case Comprehensive Cancer Center	72

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center	Cleveland	United States	13

Clinical trials